The money includes $1.4 billion in fines from Eli Lilly, the Indianapolis-based drugmaker, for promoting its antipsychotic drug Zyprexa for non-FDA-approved uses and more than $8.2 million in restitution in connection with an HIV-infusion fraud scheme in Miami.
Meanwhile, the OIG said there cannot be a national adverse event reporting system at this time because of variations in data among the 26 states that would report into the system.
Read the release about OIG healthcare fraud recoveries (pdf).
